⁸⁹Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging

<b>Background:</b> The ⁸⁹Zr radioisotope is increasingly vital in positron emission tomography (PET), especially immuno-PET, due to its long half-life of 78.4 h, allowing extended tracking of biological processes. This makes it particularly suitable for researching medicines with slow pha...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Maria-Roxana Tudoroiu-Cornoiu, Radu Marian Șerban, Diana Cocioabă, Dragoș Andrei Niculae, Doina Drăgănescu, Radu Leonte, Alina Catrinel Ion, Dana Niculae
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-06-01
Edice:	Pharmaceutics
Témata:	zirconium-89 pharmacokinetics radiopharmaceuticals HER2-positive affibody breast cancer
On-line přístup:	https://www.mdpi.com/1999-4923/17/6/739
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!